Boehringer provides update on iclepertin Phase III program in schizophrenia
Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical…
Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs
Heart disease in dogs is almost as common as it is in…
Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs
Heart disease in dogs is almost as common as it is in…
Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs
Heart disease in dogs is almost as common as it is in…
Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs
Heart disease in dogs is almost as common as it is in…
Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs
Heart disease in dogs is almost as common as it is in…
Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs
Heart disease in dogs is almost as common as it is in…
Boehringer Ingelheim Commits to Veeva Vault CRM
Top biopharma company selects the next generation of CRM for life sciences as…
Boehringer Ingelheim Commits to Veeva Vault CRM
Top biopharma company selects the next generation of CRM for life sciences as…